Welcome to our dedicated page for Check Cap news (Ticker: CHEK), a resource for investors and traders seeking the latest updates and insights on Check Cap stock.
Check-Cap Ltd. (CHEK) is a clinical-stage innovator in non-invasive screening, developing the C-Scan® ingestible capsule for colorectal cancer detection. This page provides investors and medical professionals with essential updates on the company's advancements in patient-friendly diagnostic technology.
Access authoritative updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated news collection focuses on developments directly impacting Check-Cap's position in preventive healthcare solutions, including technological refinements to its low-dose X-ray imaging system.
Key updates cover FDA communications, trial phase results, and collaborations with healthcare institutions. All content is verified through primary sources to ensure accuracy for investment and research decisions.
Bookmark this page for streamlined access to Check-Cap's evolving role in transforming colorectal screening through preparation-free technology. Monitor critical developments in medical imaging innovation and diagnostic accessibility.
Check-Cap Ltd. (NASDAQ: CHEK, CHEKZ) announced financial results for Q4 and the full year ended December 31, 2022. The company reported a net loss of $3.7 million for Q4 2022, down from $5.5 million in Q4 2021. R&D expenses for the year rose to $14.3 million from $12.3 million, while general and administrative expenses increased to $5.8 million compared to $5.0 million in 2021. The company’s cash position at year-end was $42.1 million, which is projected to fund operations into Q4 2024. However, the initiation of the powered portion of its pivotal U.S. study is postponed as current efficacy results do not meet the required goals.
Check-Cap Ltd. (NASDAQ: CHEK) provided an update on its C-Scan program in a letter from CEO Alex Ovadia. In 2022, the company enrolled over 300 patients in Israel and only 17 in the U.S. due to slow recruitment linked to state licensing for X-ray technology. The preliminary efficacy results from calibration studies did not meet goals, leading to a postponement of the powered portion of the U.S. pivotal study initially set for mid-2023. Check-Cap will conduct further data analysis, amend study protocols with the FDA, and implement a cost reduction plan to extend its cash runway.
Check-Cap Ltd. (NASDAQ: CHEK) reported financial results for Q3 2022 with a net loss of $4.7 million, compared to $4.2 million in Q3 2021. R&D expenses rose to $3.6 million from $3.0 million year-over-year, reflecting increased clinical and employee costs. The company continues efforts to expand U.S. site participation in its pivotal study for C-Scan, while experiencing slower-than-expected patient recruitment. Check-Cap executed a 1-for-20 reverse share split on November 23, 2022, resulting in approximately 5.8 million outstanding shares. Cash reserves were $46.0 million as of September 30, 2022.
Check-Cap Ltd. (NASDAQ: CHEK) reported its financial results for Q2 and six months ended June 30, 2022. The company initiated the U.S. pivotal study for C-Scan, a non-invasive colorectal cancer screening tool, at Mayo Clinic and NYU. Research and development expenses rose to $3.5 million in Q2, up from $2.8 million in 2021. Net losses increased to $4.8 million in Q2 compared to $3.9 million last year. Cash reserves decreased to $50.2 million. The company anticipates sufficient capital to fund operations through Q2 2024.
Check-Cap Ltd. (NASDAQ: CHEK) announced on June 23, 2022, that it received a 180-day extension from Nasdaq to comply with the minimum $1 bid price requirement, with a new deadline set for December 19, 2022. The company had previously failed to regain compliance after an initial notification in December 2021. If Check-Cap's share price reaches or exceeds $1 for 10 consecutive trading days before the deadline, it will regain compliance. Check-Cap is advancing its C-Scan® technology, a non-invasive colorectal cancer screening test.
Check-Cap Ltd. (NASDAQ: CHEK) reported financial results for Q1 2022, with a net loss of $5.8 million, up from $3.6 million in Q1 2021. The company initiated the U.S. pivotal study of its C-Scan® device in May 2022, aiming to enroll 1,000 subjects. R&D expenses rose to $4.1 million, influenced by increased headcount and clinical costs. General and administrative expenses also increased to $1.8 million. Cash reserves totaled $55.7 million as of March 31, 2022, ensuring operational funding through Q1 2024.
Check-Cap Ltd. (NASDAQ: CHEK) has initiated its U.S. pivotal trial for C-Scan®, a non-invasive screening test for colorectal cancer detection, at Mayo Clinic. Having received Institutional Review Board approval, the trial aims to enroll approximately 1,000 participants aged 50-75 across 15 sites. The study will assess C-Scan's accuracy in identifying polyp risks, with the first part focusing on calibration. Check-Cap's innovative approach seeks to enhance screening participation, addressing the common aversion to traditional colonoscopy procedures.
